The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
Funding & Investment
We interviewed Paul Overton, Global Head of Business Development & Marketing at Evotec, on how the world of R&D is changing in Life Sciences and what he predicts the future holds.
Read the rest of entry »
PsiOxus Therapeutics, Ltd. (PsiOxus) today announced that the Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors, has been approved and, per the licensing agreement between the parties, Bristol-Myers Squibb will make a US $15 million milestone payment to PsiOxus.
The Enterprise Europe Network (EEN), in partnership with Innovate UK is organising a funded Accelerator Programme visit to Japan for innovative UK companies operating in the Cell and Gene Therapy sector.
Wessex Clinical Research Network (CRN) and Wessex Academic Health Science Network (AHSN) have teamed up to support commercial innovators gather crucial evidence on their products. Their new Technology Support Programme (TSP) will help companies to access the NHS’s research infrastructure to obtain high quality evidence on the economic and health gains their products can bring.
Oxford MESTar, in collaboration with the Cell and Gene Therapy Catapult and AK Biomedical, has won a grant from Innovate UK to support the development of a novel manufacturing system intended to dramatically reduce the cost of production of CAR-T therapies.
Oxford Immunotec intends to use the net proceeds from the offering for working capital and general corporate purposes.
Beamline Diagnostics, developers of an innovative biopsy triaging system, founded by Dr. Liberty Foreman and Dr. Katherine Willetts, has closed a £650k investment round which was led by a syndicate of Angels in MedCity (AiMC) and other investors.
Innovation Forum Leaders Conference 2017 - 'Convergence in Bio-innovation' - 4-5 December 2017, Oxford
The Innovation Forum Leaders Conference 2017 will take place on 4th and 5th December in Oxford, UK and is an invitation only, world-leading conference supporting industry-academic collaborations and investment for early-stage ventures. Apply for an invitation. Our global conference will bring together over 400 delegates from the healthcare, biotechnology and life science sectors: Academics, start-ups, early stage ventures, SMEs, large pharmaceutical companies, prominent investors and top innovators. CEOs, prominent investors and top innovators will deliver keynote speeches and head discussions on the latest trends in therapeutics, cleantech and medtech as part of our 2-day extensive programme of presentations and workshops.
Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce that it has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.
Delivery of new therapies for metabolic disease (such as diabetes) is hampered by a paucity of single targets that are amenable to drug discovery. To address this challenge, Exscientia will apply its unique platform to identify and validate combinations of drug targets* that could work synergistically and be amenable to Exscientia’s powerful bispecific-small-molecule design strategy – where a small molecule is designed to be compatible with two distinct drug targets.
Starting with over a thousand disease-relevant target combinations, Exscientia will triage opportunities and prioritise those with promising bispecific binding potential. Target pairs fulfilling these initial tractability criteria will pa ...
Philadelphia, USA and Oxford, UK: Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”) following its entry into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”) to purchase an aggregate of approximately US$42,000,000 of its ADSs. Adaptimmune sold 7,000,000 ADSs at a price of $6.00 per ADS.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, firstname.lastname@example.org, and we will post.